1
|
Achamrah N, Nobis S, Breton J, Jésus P, Belmonte L, Maurer B, Legrand R, Bôle-Feysot C, Rego JLD, Goichon A, Rego JCD, Déchelotte P, Fetissov SO, Claeyssens S, Coëffier M. Maintaining physical activity during refeeding improves body composition, intestinal hyperpermeability and behavior in anorectic mice. Sci Rep 2016; 6:21887. [PMID: 26906060 PMCID: PMC4764812 DOI: 10.1038/srep21887] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Accepted: 02/03/2016] [Indexed: 12/18/2022] Open
Abstract
A role of gut-brain axis emerges in the pathophysiology of anorexia nervosa and maintaining adapted physical activity during refeeding remains discussed. We aimed to assess gastrointestinal protein metabolism and investigate the contribution of physical activity during refeeding in C57BL/6 mice with activity-based anorexia (ABA). ABA mice exhibited lower body weight and food intake with increase of lean mass/fat mass ratio and fat oxidation. Colonic permeability was increased in ABA. Ad libitum food access was then restored and ABA group was divided into two subgroups, with access to running wheel (ABA-PA) or not (ABA-NPA). After refeeding, fat free mass was completely restored only in ABA-PA. Colonic permeability was enhanced in ABA-NPA. Finally, muscle kynurenine conversion into kynurenic acid was lower in ABA-NPA who also exhibited altered behavior. Maintaining physical activity during refeeding may thus limit colonic hyperpermeability and improve behavior in anorectic mice.
Collapse
Affiliation(s)
- Najate Achamrah
- Normandie Univ, INSERM Unit 1073, UR, France
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, France
- Rouen University Hospital, Nutrition unit, Rouen, France
| | - Séverine Nobis
- Normandie Univ, INSERM Unit 1073, UR, France
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, France
| | - Jonathan Breton
- Normandie Univ, INSERM Unit 1073, UR, France
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, France
| | - Pierre Jésus
- Normandie Univ, INSERM Unit 1073, UR, France
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, France
| | - Liliana Belmonte
- Normandie Univ, INSERM Unit 1073, UR, France
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, France
- Rouen University Hospital, Nutrition unit, Rouen, France
| | - Brigitte Maurer
- Rouen University Hospital, Laboratory of Medical Biochemistry, Rouen, France
| | - Romain Legrand
- Normandie Univ, INSERM Unit 1073, UR, France
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, France
| | - Christine Bôle-Feysot
- Normandie Univ, INSERM Unit 1073, UR, France
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, France
| | - Jean Luc do Rego
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, France
- Animal Behavior Platform SCAC, University of Rouen, France
| | - Alexis Goichon
- Normandie Univ, INSERM Unit 1073, UR, France
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, France
| | - Jean Claude do Rego
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, France
- Animal Behavior Platform SCAC, University of Rouen, France
| | - Pierre Déchelotte
- Normandie Univ, INSERM Unit 1073, UR, France
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, France
- Rouen University Hospital, Nutrition unit, Rouen, France
| | - Sergueï O Fetissov
- Normandie Univ, INSERM Unit 1073, UR, France
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, France
| | - Sophie Claeyssens
- Normandie Univ, INSERM Unit 1073, UR, France
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, France
- Rouen University Hospital, Laboratory of Medical Biochemistry, Rouen, France
| | - Moïse Coëffier
- Normandie Univ, INSERM Unit 1073, UR, France
- Institute for Research and Innovation in Biomedicine (IRIB), University of Rouen, France
- Rouen University Hospital, Nutrition unit, Rouen, France
| |
Collapse
|
2
|
Abstract
Intravenous glutamine supplementation is standard care when parenteral nutrition is given for critical illness. There are data of a reduced mortality when glutamine supplementation is given. In addition, standard commercial products for parenteral nutrition do not contain any glutamine due to glutamine instability in aqueous solutions. For the majority of critical ill patients who are fed enterally, the available evidence is insufficient to recommend glutamine supplementation. Standard formulation of enteral nutrition contains some glutamine: 2-4 g/L. However, this dose is insufficient to normalize glutamine plasma concentration. Plasma concentration of glutamine is low in many patients with critical illness and a low level is an independent risk factor for mortality. A low plasma glutamine concentration is the best indicator of glutamine depletion. Data are emerging about how the endogenous production of glutamine is regulated. We know that skeletal muscle is the major producer of glutamine and that a part of the profound depletion of skeletal muscle seen in critical illness is a reflection of the need to produce glutamine. Glutamine is utilized in rapidly dividing cells in the splanchnic area. Quantitatively most glutamine is oxidized, but the availability of glutamine in surplus is important for the de novo synthesis of nucleotides and necessary for cell division and protein synthesis. More knowledge about the regulation of the endogenous production of glutamine is needed to outline better guidelines for glutamine supplementation in the future.
Collapse
Affiliation(s)
- Jan Wernerman
- Department of Intensive Care Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden.
| |
Collapse
|
3
|
Boukhettala N, Leblond J, Claeyssens S, Faure M, Le Pessot F, Bôle-Feysot C, Hassan A, Mettraux C, Vuichoud J, Lavoinne A, Breuillé D, Déchelotte P, Coëffier M. Methotrexate induces intestinal mucositis and alters gut protein metabolism independently of reduced food intake. Am J Physiol Endocrinol Metab 2009; 296:E182-90. [PMID: 18984853 DOI: 10.1152/ajpendo.90459.2008] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
One of the main secondary toxic side effects of antimitotic agents used to treat cancer patients is intestinal mucositis. This one is characterized by compromised digestive and absorptive functions, barrier integrity, and immune competence. At the same time, food intake is decreased, which may induce intestinal damages per se. The aim of the study was to characterize which alterations are specific to methotrexate, independently of the anorexic effect of the drug. Male Sprague-Dawley rats received subcutaneously saline solution as control group or 2.5 mg/kg of methotrexate during 3 days (D0-D2). Methotrexate-treated rats were compared with ad libitum and pair-fed controls. Histological examinations and specific markers of the immune and nonimmune gut barrier function were assessed at D4 or D7. Compared with ad libitum and pair-fed controls, methotrexate induced at D4 villus atrophy associated with epithelial necrosis. Mucosal protein synthesis rate and mucin contents of methotrexate treated rats were reduced. At the same time, cathepsin D proteolytic activity was increased compared with ad libitum and pair-fed controls, whereas calpain activity was increased when compared with the only pair-fed controls. These intestinal lesions were associated with various metabolic disturbances such as increased TNF-alpha level and inflammation score in the jejunum but also disturbances of amino acid concentrations in the duodenum and plasma. At D7, these alterations were partially or completely normalized. In addition to the consequences of a low food intake, methotrexate further impairs different biological processes leading to a dramatic loss of gut homeostasis. Targeted nutritional management of chemotherapy receiving patients should be set up to prevent or limit such alterations.
Collapse
Affiliation(s)
- Nabile Boukhettala
- ADEN EA4311, Institute for Biomedical Research, IFRMP23, 22 Boulevard Gambetta 76183 Rouen Cedex 1, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Claeyssens S, Lecleire S, Leblond J, Marion R, Hecketsweiler B, Lavoinne A, Ducrotté P, Déchelotte P, Coëffier M. Lack of effect of acute enteral arginine infusion on whole-body and intestinal protein metabolism in humans. Dig Dis Sci 2007; 52:1826-32. [PMID: 17406837 DOI: 10.1007/s10620-006-9628-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/13/2006] [Accepted: 09/27/2006] [Indexed: 12/09/2022]
Abstract
Arginine is a conditionally essential amino acid and exerts anabolic effects. We studied the effects of enteral arginine on whole-body and duodenal protein metabolism. Eight healthy fasted volunteers received randomly a 5-hr enteral infusion of either arginine (Arg; 20 g) or an isonitrogenous amino acid mixture (AA) and an IV infusion of [13C]leucine. Duodenal biopsies were performed. Whole-body protein turnover and duodenal protein synthesis (FSR) were calculated from GC/MS-assessed enrichment. The mRNA levels for major components of proteolytic pathways, ubiquitin, cathepsin D, and m-calpain, were evaluated by RT-PCR. Results were compared using paired Wilcoxon test. Endogenous, oxidative, and nonoxidative leucine fluxes were not different after Arg and AA infusions, respectively. Duodenal mucosal protein FSR (71% +/- 26% vs 81% +/- 30%/day) and mRNA levels of ubiquitin, cathepsin D, and m-calpain were also similar after Arg and AA infusions. We conclude that in healthy subjects, arginine infusion exerts no effect on whole-body and duodenal protein metabolism. Whether arginine might specifically affect these parameters in catabolic or inflammatory situations remains to be determined.
Collapse
Affiliation(s)
- Sophie Claeyssens
- Appareil Digestif, Environnement et Nutrition (ADEN EA 3234), Institut Fédératif de Recherche Multidisciplinaire sur les Peptides, and CIC-INSERM-CHU, Rouen, France
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Alpers DH. Glutamine: do the data support the cause for glutamine supplementation in humans? Gastroenterology 2006; 130:S106-16. [PMID: 16473057 DOI: 10.1053/j.gastro.2005.11.049] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/27/2004] [Accepted: 11/14/2005] [Indexed: 12/17/2022]
Abstract
This review examines the preclinical rationale for using glutamine supplements and reviews the prospective randomized trials using glutamine to improve outcomes in patients. A special role for glutamine in gut physiology and in management of a variety of serious illnesses has been suggested, because it is the most abundant extracellular amino acid, and is used at high rates by the gut, liver, central nervous system, and immune cells. A state of relative Gln deficiency has been postulated in humans based on the decrease in plasma Gln in acute critical illness, but the decrease in plasma Gln is not specific for that amino acid, predicts only poorer outcome, and has not been validated to identify a deficiency state. Current evidence does not necessarily predict a special need or role for Gln in critical illness. Clinical efficacy of supplemental Gln has been difficult to demonstrate, possibly related to the lack of a Gln deficiency state, the wide range of end points used that reflect the lack of certainty of the predicted effect of supplementation, the heterogeneous patient populations studied, the lack of stable clinical course during the study, the lack of adequate power, and the relatively short follow-up period. Prospective randomized clinical trials of Gln supplementation were reviewed in patients with short-bowel syndrome, during cancer chemotherapy and in bone marrow transplantation, and in surgical, burn, and intensive care unit patients. No firm recommendation can be made at this time. Future studies should seek to develop a more standard and stable design for intervention in sufficiently powered studies.
Collapse
Affiliation(s)
- David H Alpers
- Division of Gastroenterology, Washington University School of Medicine, St Louis, Missouri 63110, USA.
| |
Collapse
|
6
|
Coëffier M, Claeyssens S, Hecketsweiler B, Lavoinne A, Ducrotté P, Déchelotte P. Enteral glutamine stimulates protein synthesis and decreases ubiquitin mRNA level in human gut mucosa. Am J Physiol Gastrointest Liver Physiol 2003; 285:G266-73. [PMID: 12702496 DOI: 10.1152/ajpgi.00385.2002] [Citation(s) in RCA: 67] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Effects of glutamine on whole body and intestinal protein synthesis and on intestinal proteolysis were assessed in humans. Two groups of healthy volunteers received in a random order enteral glutamine (0.8 mmol.kg body wt(-1)x h(-1)) compared either to saline or isonitrogenous amino acids. Intravenous [2H5]phenylalanine and [13C]leucine were simultaneously infused. After gas chromatography-mass spectrometry analysis, whole body protein turnover was estimated from traced plasma amino acid fluxes and the fractional synthesis rate (FSR) of gut mucosal protein was calculated from protein and intracellular phenylalanine and leucine enrichments in duodenal biopsies. mRNA levels for ubiquitin, cathepsin D, and m-calpain were analyzed in biopsies by RT-PCR. Glutamine significantly increased mucosal protein FSR compared with saline. Glutamine and amino acids had similar effects on FSR. The mRNA level for ubiquitin was significantly decreased after glutamine infusion compared with saline and amino acids, whereas cathepsin D and m-calpain mRNA levels were not affected. Enteral glutamine stimulates mucosal protein synthesis and may attenuate ubiquitin-dependent proteolysis and thus improve protein balance in human gut.
Collapse
Affiliation(s)
- Moïse Coëffier
- Appareil Digestif, Environnement et Nutrition, Institut Fédératif de Recherche Multidisciplinaire sur les Peptides, Centre d' Investigation Clinique, Rouen, France
| | | | | | | | | | | |
Collapse
|